Issues of long-term use of antihistamines


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. Second-generation antihistamines (are the drugs of choice in the treatment of patients with chronic urticaria (induced, spontaneous); furthermore, long-term therapy with antihistamines is required in most cases. For long-term use of antihistamines, the safest ones should be preferred. These include cetirizine and levocetirizine, which have been shown to be safe in numerous placebo-controlled studies. Methods. The study included 27 patients with chronic urticaria. All patients received levocetirizine at a dose of 5 mg per day. To assess the effectiveness of therapy, the Urticaria Activity Score 7 (UAS7) and the Quality of Life Index were used. Results. In 23 (85.2%) patients, levocetirizine was effective with complete disease control. Long-term use of the drug for 12-18 months did not reveal significant side effects that required its withdrawal. Conclusion. The results of an observational study showed the high efficacy and safety of levocetirizine in patients with various forms of chronic urticaria in a standard dosage (5 mg per day) for 12-18 months.

全文:

受限制的访问

作者简介

Larisa Kruglova

Central State Medical Academy of Department of Presidential Affairs

Email: kruglovals@mail.ru
Dr. Sci (Med.), Professor, Vice-Rector for Academic Affairs, Head of the Department of Dermatovenereology and Cosmetology

N. Tataurschikova

RUDN University

E. Tipaeva

Saratov Regional Clinical Dermatovenerologic Dispensary

参考

  1. Holgate S.T., Canonica G.W., Simons F.E. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003:(33):1305-24. doi: 10.1046/j.1365-2222.2003.01769.x.
  2. Левина Ю.Г., Намазова-Баранова Л.С., Алексеева А.А.и др. Клинико-фармакологические особенности применения цетиризина в терапии аллергических болезней у детей. Педиатрическая фармакология. 20214;11(3):20-6.
  3. Staevska V., Popov T.A., Kralimakova T., et al. The effectiveness of levocetirizine and desloratadine in up to 4 timed conventional doses in difficult to treat urticarial. Allergy and clinical immunology. 2010:(125):676-82.
  4. Ashenager M.S. Investigating Allergollogy and Clinical Immunology. 2007:17(1):2-6.
  5. Гущин И.С., Антигистаминные препараты. М.: Aventis Pharma, 2000. 54 с.
  6. Карева Е.Н. Выбор антигистаминного препарата: взгляд фармаколога. Русский медицинский журнал. 2016:(3):811-16.
  7. Church D.S., Church M.K. Pharmacology of antihistamines. World Allergy Organ J. 2011:(4):S22-S27. Doi: 10.1097/ WOX.0b013e3181f385d9.
  8. Фомина Д.С., Горячкина Л.А. Выбор антигиста -минного препарата с позиции доказательной медицины. Эффективная фармакотерапия. Аллергология и иммунология. 2012:(1):18-24
  9. Church M., Maurer M., Simons F., et al. Global Allergy and Asthma European Network. Risk of first generation H1 antihistamines: a GA(2)LEN position paper. Allergy 2010:(65):459-66. doi: 10.1111/j.1398-9995.2009.02325.x.
  10. Рандомизированное открытое сбалансированное двухкомпонентное двухпериодное перекрестно, с однократным приемом препарата исследование сравнительной фармакокинетики и биоэквивалентности лекарственного препарата Левоцетиризин («Д-р Редди’с ЛабораторисЛтд.», Индия) и Ксизал® (левоцетиризин), производства «ЮСБ Фаршим С.А.» (Швейцария), в лекарственной форме таблетки, покрытые пленочной оболочкой, 5 мг, на здоровых взрослых добровольцах натощак, DRL_RUS/MDR/KCT/2014/LCZN
  11. Bachert C., Bousquet J., Canonica G.W., et al. XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004;114(4):838-44. doi: 10.1016/j.jaci.2004.05.070.
  12. Diepgen T.L. Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. 2002;13(4):278-86. doi: 10.1034/j.1399-3038.2002.01047.x.
  13. Hussein Z., Pitsiu M., Majid O., et al. ETAC Study Group. Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study Br J. Clin Pharmacol. 2005;59(1):28-37. doi: 10.1111/j.1365-2125.2005.02242.x.
  14. Simons F.E. Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol. 2007;18(6):535-42. doi: 10.1111/j.1399-3038.2007.00558.x.
  15. Zuberbier T.A. Summary of the New International EAACI/GA (2)LEN/EDF/WAO Guidelines in Urticaria. World Allergy Organ J. 2012;5(Suppl 1):S1-5. Doi: 10.1097/ W0X.0b013e3181f13432.
  16. Zuberbier T., Asero R., Bindslev-Jensen C., et al. EAACI/GA2 LEN/EDF/WAO guideline: management of urticarial. Allergy 2009;64:1427-43. doi: 10.1111/j.1398-9995.2009.02178.x.
  17. Ненашева Н.М. и др. Сезонный аллергический ринит и его контроль антигистаминными препаратами в условиях амбулаторной практики. Российский аллергологический журнал. 2020;17(2):44-52.
  18. Staevska M., et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin Immunol. 2010;125:676-82. doi: 10.1016/j.jaci.2009.11.047.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##